文献速递乳腺癌

HER2阳性乳腺癌新辅助双靶向HER2阻断的十年生存

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
PubMed 文献 · Eur J Cancer · 2022-12-27

NeoALTTO研究纳入455例HER2阳性早期乳腺癌患者,随机接受拉帕替尼、曲妥珠单抗或两药联合新辅助治疗。十年无事件生存率三组分别为63%、64%和67%,总生存率分别为76%、75%和80%。达到病理完全缓解者无事件生存(HR 0.48)和总生存(HR 0.37)均显著优于未达到者。

要点

  • 新辅助双靶向HER2阻断的十年生存获益在各治疗组均持久。
  • 达到病理完全缓解者无事件生存HR 0.48、总生存HR 0.37。
  • 未观察到新的或长期安全性问题。

核心结论

  • HER2阳性乳腺癌患者新辅助抗HER2治疗显示持久的生存获益,与治疗组别无关。
  • 达到病理完全缓解的患者结局显著优于未达到病理完全缓解的患者。

研究设计与样本

  • NeoALTTO(NCT00553358)为国际、随机、开放标签、III期研究,在HER2阳性早期乳腺癌中探讨在化疗联合曲妥珠单抗基础上加用拉帕替尼。
  • 意向治疗人群共455例,随机分配至拉帕替尼组154例、曲妥珠单抗组149例、联合组152例。
  • 评估十年无事件生存、总生存和安全性,并在界标人群中分析病理完全缓解与无事件生存或总生存的关联。

主要发现

  • 十年无事件生存率:拉帕替尼组63%(95%CI 54%-71%),曲妥珠单抗组64%(95%CI 55%-72%),联合组67%(95%CI 58%-74%)。
  • 十年总生存率:拉帕替尼组76%(95%CI 67%-83%),曲妥珠单抗组75%(95%CI 66%-82%),联合组80%(95%CI 73%-86%)。
  • 达到病理完全缓解者较未达到者无事件生存改善(HR 0.48,95%CI 0.31-0.73),总生存改善(HR 0.37,95%CI 0.20-0.63)。
  • 按病理完全缓解状态划分的生存数值差异在联合组和激素受体阴性肿瘤患者中更大。
  • 未观察到新的或长期安全性问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR. METHODS: Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population. RESULTS: A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%-71%) in the lapatinib group, 64% (95% CI, 55%-72%) in the trastuzumab group and 67% (95% CI, 58%-74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%-83%), 75% (95% CI, 66%-82%) and 80% (95% CI, 73%-86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and OS (hazard ratio 0.37, 95% CI, 0.20-0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns. CONCLUSIONS: Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nuciforo P, Townend J, Piccart MJ, et al. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2022. PMID: 36641898. doi:10.1016/j.ejca.2022.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。